The quest for effective HIV prevention and treatment faces a critical challenge: the virus's remarkable ability to evolve resistance against even our most promising therapeutic antibodies. This reality threatens the clinical potential of broadly neutralizing antibodies, which had emerged as a beacon of hope for durable HIV control.
Deep genomic analysis of HIV envelope genes from 20 patients receiving monotherapy with either 10-1074 or 3BNC117 antibodies reveals dramatically different viral escape strategies. Against 10-1074, HIV consistently employs a limited repertoire of previously documented resistance mutations that emerge repeatedly across diverse patient populations. These mutations can exist as rare variants before treatment begins, though their presence doesn't predict when viral rebound will occur. Importantly, not all available escape routes are equally favored by the virus.
The 3BNC117 antibody faces a more complex resistance landscape. HIV populations develop highly individualized escape patterns, with specific mutations rarely transferring between different host environments unless the viral strains are closely related. Yet even within this personalized resistance framework, certain mutations still emerge repeatedly within individual patients.
These findings expose the sophisticated evolutionary dynamics underlying HIV's resistance mechanisms and highlight why single-antibody treatments consistently fail. The research demonstrates that effective therapeutic strategies must account for both the predictable resistance pathways seen with some antibodies and the host-specific escape patterns characteristic of others. This knowledge becomes crucial for designing combination antibody therapies that can outmaneuver HIV's adaptive capabilities and provide sustained viral suppression across diverse patient populations.